Literature DB >> 33503944

How Do Pharmaceutical Companies Overcome a Corporate Productivity Crisis? Business Diversification into Medical Devices for Growth Potential.

Yoonje Euh1, Daeho Lee1.   

Abstract

The purpose of this study was to analyze the performance of pharmaceutical companies' business diversification into medical devices in terms of their technical efficiency (TE) as compared to that of traditional pharmaceutical companies. For a total of 174 externally audited pharmaceutical companies engaged in the drug product business between 2008 and 2019, pharmaceutical companies were classified into two groups according to medical device business diversification. The TE of pharmaceutical companies that diversify the medical device business was lower than that of traditional pharmaceutical companies. However, in terms of the meta-technology ratio (MTR) calculated using meta-frontier analysis, pharmaceutical companies diversified into medical devices showed higher MTR than the traditional pharmaceutical company group. The results imply that the corporate performance growth potential of traditional pharmaceutical companies is lower than that of pharmaceutical companies that have diversified into the medical device business.

Entities:  

Keywords:  business diversification; medical device; meta-frontier analysis; pharmaceutical company; technical efficiency

Mesh:

Substances:

Year:  2021        PMID: 33503944      PMCID: PMC7908371          DOI: 10.3390/ijerph18031045

Source DB:  PubMed          Journal:  Int J Environ Res Public Health        ISSN: 1660-4601            Impact factor:   3.390


  16 in total

1.  The changing structure of the pharmaceutical industry.

Authors:  Iain M Cockburn
Journal:  Health Aff (Millwood)       Date:  2004 Jan-Feb       Impact factor: 6.301

Review 2.  The importance of new companies for drug discovery: origins of a decade of new drugs.

Authors:  Robert Kneller
Journal:  Nat Rev Drug Discov       Date:  2010-10-29       Impact factor: 84.694

3.  Productivity in pharmaceutical-biotechnology R&D: the role of experience and alliances.

Authors:  Patricia M Danzon; Sean Nicholson; Nuno Sousa Pereira
Journal:  J Health Econ       Date:  2005-01-25       Impact factor: 3.883

Review 4.  Pharmaceutical strategy and innovation: an academics perspective.

Authors:  Ian R Baxendale; John J Hayward; Steven V Ley; Geoffrey K Tranmer
Journal:  ChemMedChem       Date:  2007-06       Impact factor: 3.466

5.  How to revive breakthrough innovation in the pharmaceutical industry.

Authors:  Bernard H Munos; William W Chin
Journal:  Sci Transl Med       Date:  2011-06-29       Impact factor: 17.956

6.  Is poor research the cause of the declining productivity of the pharmaceutical industry? An industry in need of a paradigm shift.

Authors:  Frank Sams-Dodd
Journal:  Drug Discov Today       Date:  2012-11-03       Impact factor: 7.851

7.  The COVID-19 vaccine development landscape.

Authors:  Tung Thanh Le; Zacharias Andreadakis; Arun Kumar; Raúl Gómez Román; Stig Tollefsen; Melanie Saville; Stephen Mayhew
Journal:  Nat Rev Drug Discov       Date:  2020-05       Impact factor: 84.694

8.  Medical device development: managing conflicts of interest encountered by physicians.

Authors:  Donald S Baim; Aine Donovan; John J Smith; Nancy Briefs; Richard Geoffrion; David Feigal; Aaron V Kaplan
Journal:  Catheter Cardiovasc Interv       Date:  2007-04-01       Impact factor: 2.692

9.  Emergence of a Novel Coronavirus Disease (COVID-19) and the Importance of Diagnostic Testing: Why Partnership between Clinical Laboratories, Public Health Agencies, and Industry Is Essential to Control the Outbreak.

Authors:  Matthew J Binnicker
Journal:  Clin Chem       Date:  2020-05-01       Impact factor: 8.327

Review 10.  Emerging technologies for diagnostics and drug delivery in the fight against COVID-19 and other pandemics.

Authors:  Dimitrios A Lamprou
Journal:  Expert Rev Med Devices       Date:  2020-07-17       Impact factor: 3.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.